A REAL-WORLD STUDY EVALUATING EFFECTIVENESS AND SAFETY OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY AFTER TAFASITAMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: AN ITALIAN SUBGROUP ANALYSIS (SIE 2026) - Oct 6, 2026 - Abstract #DP054; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; "Here we report data from the Italian subgroup.Adult R/R DLBCL pts treated with tafa (± lenalidomide) followed by CAR-T in second line (2L), 3L, or 4L were included; pts had ≥6 mo of follow-up post CAR-T except in the event of death, and were followed until the start of new anticancer tx after CAR-T, end of data avail- ability, or death, whichever occurred first...Consistent with overall study results, CAR-T was administered predomi- nantly in 3L (36 [61.0%]) and 4L (15 [25.4%]); axi-cel was the most frequent CAR-T tx used (39 [66.1%])...Severe (grade ≥3) CRS and ICANS occurred in 25 (7.4%) and 13 (3.8%) pts, respectively, in the overall study population, and in 1 (1.7%) pt each in the Italian cohort.Results from this Italian subgroup analysis are similar to those of the overall popula- tion. Findings add to increasing evidence demonstrating that tafa exposure does not appear to compromise the effec- tiveness and safety of subsequent CAR-T among R/R DLBCL..."
CAR T-Cell Therapy • Clinical • IO biomarker • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • CD19
|
|
A. Di Rocco1; N. Epperla2; K. Saverno3; I. Pivneva4; S. Sethi5; L. Sackmann3; A. Zaffalon3; J. Wu3; M. Bastos-Oreiro6
|